Taiwan: PharmaEssentia raises US$462.7m from upsized GDS

PharmaEssentia Corp, a fully integrated biopharmaceutical company has raised US$462.7m from an upsized global depositary share (GDS) offering, according to IFR. The issuance is a large one to digest, says Ethan Aw of Aequitas Research in a note published on SmartKarma, as it represents over 17 days of three month average daily volumes. Nevertheless, the…

You must be a HMI Subscriber to view this content.

Subscribe Now »